

References

Chapter 3

- 1 Wettermark B. The intriguing future of pharmacoepidemiology. *European Journal of Clinical Pharmacology*. 2013;**69**(Suppl. 1):43–51.
- 2 Persaud N. Primary data source. In: Salkind NJ, ed. *Encyclopedia of Research Design*. SAGE Publications, 2010: 1095–8.
- 3 Kothari C, Garg G. *Research Methodology: Methods and Techniques*, 3rd edn. New Delhi, New Age Publications, 2014.
- 4 Rothman K, Greenland S, Lash T. *Modern Epidemiology*, 3rd edn. Philadelphia, PA, Lippincott Williams & Wilkins, 2008.
- 5 Kornegay C, Segal J. Selection of data sources In: Velentgas PDN, Nourjah P, et al., eds. *Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide*. Rockville, MD, Agency for Healthcare Research and Quality, 2013: 109–28. AHRQ Publication 12(13)-EHC099.
- 6 Szklo M, Nieto J. *Epidemiology: Beyond the Basics*, 3rd edn. Sudbury, Jones and Bartlett Publishers, 2012.
- 7 Miettinen OS. *Epidemiological Research: Terms and Concepts*. Dordrecht, Springer, 2011.
- 8 Porta M. *A Dictionary of Epidemiology*, 5th edn. New York, Oxford University Press, 2008.
- 9 Schultze U, Avital M. Designing interviews to generate rich data for information systems research. *Information and Organization*. 2011;**21**(1):1–16.
- 10 Nielsen MW, Sondergaard B, Kjoller M, Hansen EH. Agreement between self-reported data on medicine use and prescription records vary according to method of analysis and therapeutic group. *Journal of Clinical Epidemiology*. 2008;**61**(9):919–24.
- 11 Van den Brandt PA, Petri H, Dorant E, Goldbohm RA, Van de Crommert S. Comparison of questionnaire information and pharmacy data on drug use. *Pharmaceutisch weekblad. Scientific Edition*. 1991;**13**(2):91–6.
- 12 Loo RL, Chan Q, Brown IJ, et al. A comparison of self-reported analgesic use and detection of urinary ibuprofen and acetaminophen metabolites by means of metabonomics: the INTERMAP Study. *Am J Epidemiol*. 2012;**175**(4):348–58.
- 13 Vancheri F, Strender L, Backlund L. General practitioners' coronary risk estimates, decisions to start lipid-lowering treatment, gender and length of clinical experience: their interactions in primary prevention. *Primary Health Care Research & Development*. 2013;**14**(4):394–402.
- 14 Deepmala D, Franz L, Aponte C, Agrawal M, Jiang W. Identification of provider characteristics influencing prescription of analgesics: a systematic literature review. *Pain Practice*. 2013;**13**(6):504–13.
- 15 Pai R, Ramji A, Lee S, Wong W, Yoshida E. Chronic hepatitis C in Western Canada: a survey of practice patterns among gastroenterologists in Alberta and British Columbia. *Canadian Journal of Gastroenterological Hepatology*. 2014;**28**(1):e1–4.
- 16 Wolfert M, Gilson A, Dahl J, Cleary J. Opioid analgesics for pain control: Wisconsin physicians' knowledge, beliefs, attitudes, and prescribing practices. *Pain Medicine*. 2010;**11**(3):425–34.
- 17 Thorpe C, Ryan B, McLean S, et al. How to obtain excellent response rates when surveying physicians. *Family Practice*. 2009;**26**(1):65–8.
- 18 Bjertnaes O, Garratt A, Botten G. Nonresponse bias and cost-effectiveness in a Norwegian survey of family physicians. *Evaluation & The Health Professions*. 2008;**31**(1):65–80.
- 19 VanGeest J, Johnson T, Welch V. Methodologies for improving response rates in surveys of physicians: a systematic review. *Evaluation & The Health Professions*. 2007;**30**(4):303–21.

- 20** Bertsche T, Niemann D, Mayer Y, Ingram K, Hoppe-Tichy T, Haefeli W. Prioritising the prevention of medication handling errors. *Pharmacy World & Science*. 2008;**30**(6):907–15.
- 21** Bhanbhro S, Drennan V, Grant R, Harris R. Assessing the contribution of prescribing in primary care by nurses and professionals allied to medicine: a systematic review of literature. *BMC Health Services Research*. 2011;**11**:330.
- 22** Braund R, Coulter C, Bodington A, et al. Drug related problems identified by community pharmacists on hospital discharge prescriptions in New Zealand. *International Journal of Clinical Pharmacy*. 2014;**36**(3):498–502.
- 23** Pedersen C, Schneider P, Scheckelhoff D. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing – 2013. *American Journal of Health Systems Pharmacy*. 2014;**71**(11):924–42.
- 24** Schommer J, Gaither C. A segmentation analysis for pharmacists' and patients' views of pharmacists' roles. *Research in Social & Administrative Pharmacy*. 2014;**10**(3):508–28.
- 25** Hughes C, Hawwa A, Scullin C, et al. Provision of pharmaceutical care by community pharmacists: a comparison across Europe. *Pharmacy World & Science*. 2010;**32**:472–87.
- 26** Worley M, Schommer J, Brown L, et al. Pharmacists' and patients' roles in the pharmacist-patient relationship: are pharmacists and patients reading from the same relationship script? *Research in Social & Administrative Pharmacy*. 2007;**3**(1):47–69.
- 27** Hutchison M, Lindblad A, Guirguis L, Cooney D, Rodway M. Survey of Alberta hospital pharmacists' perspectives on additional prescribing authorization. *American Journal of Health Systems Pharmacy*. 2012;**69**(22):1983–92.
- 28** Kierkegaard P. E-prescription across Europe. *Health Technology*. 2013;**3**:205–19.
- 29** Olsen J. Register-based research: some methodological considerations. *Scandinavian Journal of Public Health*. 2011;**39**:225–9.
- 30** Chen Y, Briesacher B. Use of instrumental variable in prescription drug research with observational data: a systematic review. *Journal of Clinical Epidemiology*. 2011;**64**(6):687–700.
- 31** Perini E, Junqueira DRG, Lana LGC, Luz TCB. Prescription, dispensation and marketing patterns of methylphenidate. *Revista de Saúde Pública*. 2014;**48**(6):873–80.
- 32** Desalegn A. Assessment of drug use pattern using WHO prescribing indicators at Hawassa University Teaching and Referral Hospital, south Ethiopia: a cross-sectional study. *BMC Health Services Research*. 2013;**13**(170).
- 33** Chu C, Rudant E, Bonvalet M, et al. Generic drug prescriptions following hospital discharge: a prospective study in France. *European Journal of Internal Medicine*. 2011;**22**:e45–9.
- 34** Siqueira J, Antonioli A, Silvestre C, et al. Analysis of the quality of prescriptions at a cardiovascular ward in Brazil: a pilot study. *International Journal of Clinical Pharmacy*. 2011;**33**(2):260–3.
- 35** Al Shahaibi N, Al Said L, Kini T, Chitme H. Identifying errors in handwritten outpatient prescriptions in Oman. *Journal of Young Pharmacists*. 2012;**4**(4):267–72.
- 36** Winslow E, Nestor V, Davidoff S, Thompson P, Borum J. Legibility and completeness of physicians' handwritten medication orders. *Heart Lung*. 1997;**26**:158–64.
- 37** Saczynski JS, McManus DD, Goldberg RJ. Commonly used data-collection approaches in clinical research. *American Journal of Medicine*. 2013;**126**(11):946–50.
- 38** Bai J, Mukherjee D, Befus M, Apa Z, Lowy F, Larson E. Concordance between medical records and interview data in correctional facilities. *BMC Medical Research Methodology*. 2014;**9**(14):50.
- 39** World Health Organization. *Introduction to Drug Utilization Research*. Oslo, WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services, 2003.
- 40** Harpe S. Using secondary data sources for pharmacoepidemiology and outcomes research. *Pharmacotherapy*. 2009;**29**(2):138–53.
- 41** Takahashi Y, Nishida Y, Asai S. Utilization of health care databases for pharmacoepidemiology. *European Journal of Clinical Pharmacology*. 2012;**68**(2):123–9.
- 42** Widdifield J, Bernatsky S, Paterson J, et al. Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of

- rheumatologists. *Arthritis Care Research (Hoboken)*. 2013;**65**(10):1582–91.
- 43 Rikala M, Hartikainen S, Sulkava R, Korhonen M. Validity of the Finnish prescription register for measuring psychotropic drug exposures among elderly Finns: a population-based intervention study. *Drugs Aging*. 2010;**27**(4):337–49.
- 44 Noize P, Bazin F, Dufouil C, et al. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. *Pharmacoepidemiol Drug Safety*. 2009;**18**(4):310–19.
- 45 Haukka J, Suvisaari J, Tuulio-Henriksson A, Lönnqvist J. High concordance between self-reported medication and official prescription database information. *European Journal of Clinical Pharmacology*. 2007;**63**:1069–74.
- 46 Goettsch W, Heintjes E, Kastelein J, Rabelink T, Johansson S, Herings R. Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study. *Pharmacoepidemiol Drug Safety*. 2006;**15**:435–43.
- 47 Harwood E, Vang P. Data collection methods series. Part 1: define a clear purpose for collecting data. *Journal of Wound, Ostomy, and Continence Nursing*. 2009;**36**(1):15–19.
- 48 Harwood E. Data collection methods series. Part 3: developing protocols for collecting data. *Journal of Wound, Ostomy, and Continence Nursing*. 2009;**36**(3):246–50.
- 49 Harwood E, Hutchinson E. Data collection methods series. Part 6: managing collected data. *Journal of Wound, Ostomy, and Continence Nursing*. 2009;**36**(6):592–9.
- 50 Harwood E, Hutchinson E. Data collection methods series. Part 2: select the most feasible data collection mode. *Journal of Wound, Ostomy, and Continence Nursing*. 2009;**36**(2):129–35.
- 51 Harwood E, Hutchinson E. Data collection methods series. Part 5: training for data collection. *Journal of Wound, Ostomy, and Continence Nursing*. 2009;**36**(5):476–81.
- 52 Hutchinson E, Harwood E. Data collection methods series. Part 4: designing forms and instruments. *Journal of Wound, Ostomy, and Continence Nursing*. 2009;**36**(4):371–5.
- 53 Doody O, Noonan M. Preparing and conducting interviews to collect data. *Nurse Researcher*. 2013;**20**(5):28–32.
- 54 Pan L, Fergusson D, Schweitzer I, Hebert P. Ensuring high accuracy of data abstracted from patient charts: the use of a standardized medical record as a training tool. *Journal of Clinical Epidemiology*. 2005;**58**(9):918–23.
- 55 Reisch L, Fosse J, Beverly K, et al. Training, quality assurance, and assessment of medical record abstraction in a multisite study. *American Journal of Epidemiology*. 2003;**157**(6):546–51.
- 56 Murray P. Fundamental issues in questionnaire design. *Accident and Emergency Nursing*. 1999;**7**(3):148–53.
- 57 Kimberlin C, Winterstein A. Validity and reliability of measurement instruments used in research. *American Journal of Health Systems Pharmacy*. 2008;**65**(23):2276–84.
- 58 Rattray J, Jones M. Essential elements of questionnaire design and development. *Journal of Clinical Nursing*. 2007;**16**(2):234–43.
- 59 Marshall G. The purpose, design and administration of a questionnaire for data collection. *Radiography*. 2005;**11**(2):131–6.
- 60 Carr A, Higginson I. Are quality of life measures patient centred? *British Medical Journal*. 2001;**322**(7298):1357–60.
- 61 Schechter S. Questionnaire design. In: Armitage P, Colton T, eds. *Encyclopedia of Biostatistics*, 2nd edn. Chichester, John Wiley & Sons, 2005.
- 62 Edwards P. Questionnaires in clinical trials: guidelines for optimal design and administration. *Trials*. 2010;**11**:2.
- 63 Burns K, Duffett M, Kho M, et al. A guide for the design and conduct of self-administered surveys of clinicians. *CMAJ*. 2008;**179**(3):245–52.
- 64 Streiner D, Norman G., Cairney J *Health Measurement Scales: A Practical Guide to their Development and Use*, 5th edn. Oxford, Oxford University Press, 2015.
- 65 Oppenheim A. *Questionnaire Design, Interviewing and Attitude Measurement*. London, Continuum, 1992.
- 66 Ritchie J, Lewis J. *Qualitative Research Practice: A Guide for Social Science Students and Researchers*. London, SAGE Publications, 2003.
- 67 Epstein J, Santo RM, Guillemin F. A review of guidelines for cross-cultural adaptation of questionnaires could not bring out a consensus. *J Clin Epidemiol*. 2015 Apr;**68**(4):435–41.
- 68 Uijen AA, Heinst CW, Schellevis FG, van den Bosch WJ, van de Laar FA, Terwee CB, Schers HJ. Measurement properties of questionnaires measuring

- continuity of care: a systematic review. *PLoS ONE*. 2012;**7**(7):e42256.
- 69 Reeve BB, Wyrwich KW, Wu AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. *Quality of Life Research*. 2013;**22**(8):1889–905.
- 70 Gama H, Correia S, Lunet N. Questionnaire design and the recall of pharmacological treatments: a systematic review. *Pharmacoepidemiological Drug Safety*. 2009;**18**(3):175–87.
- 71 Bertoldi A, Barros A, Wagner A, Ross-Degnan D, Hallal P. A descriptive review of the methodologies used in household surveys on medicine utilization. *BMC Health Services Research*. 2008;**8**:222.
- 72 Boynton P, Greenhalgh T. Selecting, designing, and developing your questionnaire. *British Medical Journal*. 2004;**328**(7451):1312–15.
- 73 Chaipichit N, Krska J, Pratipanawatr T, Uchaipichat V, Jarernsripornkul N. A qualitative study to explore how patients identify and assess symptoms as adverse drug reactions. *European Journal of Clinical Pharmacology*. 2014;**70**(5):607–15.
- 74 Luz T, Loyola Filho A, Lima-Costa M. Social capital and under-utilization of medication for financial reasons among elderly women: evidence from two Brazilian health surveys. *Cien Saude Colet*. 2013;**18**(12):3721–30.
- 75 Van Bever E, Elseviers M, Plovie M, Vandeputte L, Van Bortel L, Vander Stichele R. Attitudes of physicians and pharmacists towards international non-proprietary name prescribing in Belgium. *Basic & Clinical Pharmacology & Toxicology*. 2015;**116**(3):264–72.
- 76 Piette J, Wagner T, Potter M, Schillinger D. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. *Medical Care*. 2004;**42**(2):102–9.
- 77 Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. *Controlled Clinical Trials*. 2004;**25**(6):535–52.
- 78 Davidson M, Keating J. Patient-reported outcome measures (PROMs): how should I interpret reports of measurement properties? A practical guide for clinicians and researchers who are not biostatisticians. *British Journal of Sports Medicine*. 2014;**48**(9):792–6.
- 79 Anker S, Agewall S, Borggrefe M, et al. The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. *European Heart Journal*. 2014;**35**(30):2001–9.
- 80 Giesinger K, Hamilton D, Jost B, Holzner B, Giesinger J. Comparative responsiveness of outcome measures for total knee arthroplasty. *Osteoarthritis Cartilage*. 2014;**22**(2):184–9.
- 81 Cella D, Gershon R, Lai JS, Choi S. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. *Quality of Life Research*. 2007;**16**(Suppl. 1):133–41.
- 82 Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B; Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Patient-reported outcomes: conceptual issues. *Value Health*. 2007;**10**(Suppl. 2):S66–75.
- 83 EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. *Health Policy*. 1990;**16**(3):199–208.
- 84 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Medical Care*. 1992;**30**(6):473–83.
- 85 Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. *Journal of Health Economics*. 2002;**21**(2):271–92.
- 86 Valderas JM, Ferrer M, Mendivil J, Garin O, Rajmil L, Herdman M, Alonso J; Scientific Committee on ‘Patient-Reported Outcomes’ of the IRYSS Network. Development of EMPRO: A tool for the standardized assessment of patient-reported outcome measures. *Value in Health*. 2008;**11**(4):700–8.
- 87 Food and Drug Administration/Center for Drug Evaluation and Research. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. FDA, 2009. Available from: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf>9 (last accessed 18 November 2015).
- 88 Snyder CF, Watson ME, Jackson JD, Cella D, Halyard MY; Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Patient-reported outcome instrument selection: designing a measurement strategy. *Value in Health*. 2007;**10**(Suppl. 2):S76–85.
- 89 Basch E. New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. *Annual Review of Medicine*. 2014;**65**:307–17.

-
- 90** Calvert M, Kyte D, Duffy H, et al. Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. *PLoS ONE*. 2014;**9**(10):e110216.
- 91** World Health Organization. Standards and Operational Guidance for Ethics Review of Health-Related Research with Human Participants 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241502948_eng.pdf?ua=1 (last accessed 18 November 2015).
- 92** Persaud I. Field study. In: Salkind NJ, ed. *Encyclopedia of Research Design*. Sage Publications, 2010: 489–91.
- 93** World Health Organization and Council for International Organizations of Medical Sciences. *International Ethical Guidelines for Biomedical Research Involving Human Subjects*. Geneva, World Health Organization, 2002. Available from: http://www.cioms.ch/publications/layout_guide2002.pdf (last accessed 18 November 2015).
- 94** World Medical Association. *Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects*. World Medical Association, 1964. Available from: <http://www.wma.net/en/30publications/10policies/b3/> (last accessed 18 November 2015).